Biofrontera Inc. - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
BFRI Nasdaq 3840 www.biofrontera-us.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biofrontera Inc.

Biofrontera Inc. to Report First Quarter FY 2025 Financial Results on May 15, 2025 - May 6th, 2025 4:45 pm
Biofrontera and Almirall Launch the Hats On Challenge to Raise Awareness and Support for Actinic Keratosis - May 1st, 2025 6:38 pm
Biofrontera Full Year 2024 Earnings: Misses Expectations - Mar 22nd, 2025 2:06 pm
Biofrontera Inc (BFRI) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amidst Financial ... - Mar 22nd, 2025 7:01 am
Q4 2024 Biofrontera Inc Earnings Call - Mar 22nd, 2025 3:54 am
Biofrontera Inc. Reports Record Fiscal Year 2024 Financial Results and Provides a Business Update - Mar 21st, 2025 12:00 pm
Biofrontera Inc. Announces Completion of Patient Enrollment in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Actinic Keratoses on the Extremities, Neck and Trunk - Mar 18th, 2025 1:30 pm
Biofrontera Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 21, 2025 - Mar 11th, 2025 2:00 pm
When Will Biofrontera Inc. (NASDAQ:BFRI) Turn A Profit? - Feb 22nd, 2025 12:57 pm
Biofrontera Inc. Announces Achievement of Key Milestone In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Jan 8th, 2025 2:50 pm
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market - Dec 23rd, 2024 2:30 pm
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - Dec 3rd, 2024 4:00 pm
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note - Nov 22nd, 2024 2:10 pm
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ... - Nov 15th, 2024 7:12 am
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates - Nov 14th, 2024 12:10 am
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update - Nov 13th, 2024 10:15 pm
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024 - Nov 1st, 2024 4:55 pm
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Oct 31st, 2024 2:32 pm
Rosalind Advisors, Inc. Reduces Stake in Biofrontera Inc - Oct 23rd, 2024 11:01 pm
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC) - Oct 14th, 2024 2:30 pm